A Phase 2a Randomized, Observer-blind, Dose-finding Study to Evaluate the Immunogenicity and Safety of mRNA-based Multivalent Seasonal Influenza Vaccine Candidates in Adults 18 Years of Age and Older
Latest Information Update: 11 Mar 2025
At a glance
- Drugs GSK 4382276 A (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors GSK
- 09 Jan 2025 Planned End Date changed from 27 Jun 2025 to 6 Jun 2025.
- 09 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 11 Nov 2024 Planned number of patients changed from 500 to 838.